Oncothyreon and Array start phase 1b ONT-380 combination trial to treat metastatic HER2+ breast cancer

US-based Oncothyreon and Array BioPharma have started a phase 1b trial of ONT-380 (ARRY-380) in combination with Xeloda (capecitabine) and/or Herceptin (trastuzumab) for the treatment of patients with metastatic HER2+ breast cancer.

Source: Drug Development Technology - February 4, 2014 Category: Pharmaceuticals Source Type: news